Literature DB >> 31725148

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL.

Jing Pan1, Shiyu Zuo2, Biping Deng3, Xiuwen Xu4, Chuo Li2, Qinlong Zheng4, Zhuojun Ling5, Weiliang Song5, Jinlong Xu5, Jiajia Duan5, Zelin Wang5, Xinjian Yu4, Alex H Chang6, Xiaoming Feng2,7, Chunrong Tong5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31725148     DOI： 10.1182/blood.2019003293

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  33 in total

1.  BiTEs better than CAR T cells.

Authors:  Marion Subklewe
Journal:  Blood Adv       Date:  2021-01-26

2.  The one-two punch (of CAR T cells).

Authors:  Nirali N Shah
Journal:  Blood       Date:  2020-01-30       Impact factor: 22.113

3.  Relapsed ALL: CAR T vs transplant vs novel therapies.

Authors:  Noelle V Frey
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

Authors:  Andrew H Ko; Alexander C Jordan; Evan Tooker; Simon F Lacey; Renee B Chang; Yan Li; Alan P Venook; Margaret Tempero; Lloyd Damon; Lawrence Fong; Mark H O'Hara; Bruce L Levine; J Joseph Melenhorst; Gabriela Plesa; Carl H June; Gregory L Beatty
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 5.  Acute Leukemia in Infants.

Authors:  Azada Ibrahimova; Lauren Pommert; Erin H Breese
Journal:  Curr Oncol Rep       Date:  2021-02-12       Impact factor: 5.075

Review 6.  Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.

Authors:  Emiliano Roselli; Rawan Faramand; Marco L Davila
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 7.  Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Hiroto Inaba; Ching-Hon Pui
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

Review 8.  Clinical development of CAR T cell therapy in China: 2020 update.

Authors:  Jianshu Wei; Yelei Guo; Yao Wang; Zhiqiang Wu; Jian Bo; Bin Zhang; Jun Zhu; Weidong Han
Journal:  Cell Mol Immunol       Date:  2020-09-30       Impact factor: 11.530

9.  A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Authors:  Ying Zhang; Jiaqi Li; Xiaoyan Lou; Xiaochen Chen; Zhou Yu; Liqing Kang; Jia Chen; Jin Zhou; Xiangping Zong; Zhen Yang; Minghao Li; Nan Xu; Sixun Jia; Hongzhi Geng; Guanghua Chen; Haiping Dai; Xiaowen Tang; Lei Yu; Depei Wu; Caixia Li
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

10.  Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL.

Authors:  Yuan Meng; Biping Deng; Luan Rong; Chuo Li; Weiliang Song; Zhuojun Ling; Jinlong Xu; Jiajia Duan; Zelin Wang; Alex H Chang; Xiaoming Feng; Xiujuan Xiong; Xiaoli Chen; Jing Pan
Journal:  Front Oncol       Date:  2021-06-30       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.